The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06520891

Enrollment

Registered

2024-07-25

Start date

2024-06-01

Completion date

2025-12-30

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

2 Drugs Are Statin and SGLT2i

Brief summary

correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)

Detailed description

This is a prospective study that will carried out in Department of cardiology, Faculty of Medicine, Fayoum University during the period from 1 April 2024 to 1 Juley 2024. The study includes 90 Outpatients Clinic patients who met the inclusion criteria. Patients will provide written informed consent before involving in this study. * we will split the 90 patients into three groups: 1. 30 patients will take statin. 2. 30 patients will take SGLT2i. 3. 30 patients will take both of statin and SGLT2i. * By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one, we will follow their cholesterol, triglyceride, low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects.

Interventions

DRUGStatin and SGLT2i

Statin as atrovastatin SGLT2i as dapagliflozin

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Inclusion criteria

* we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease, * They assessed the use of statin with SGLT2i.

Exclusion criteria

* We exclude patients with 1. liver dysfunction. 2. renal dysfunction. 3. fungal infection. 4. coagulation disorder. 5. Pts using drugs that interact with SGLT2i. 6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.

Design outcomes

Primary

Measure	Time frame	Description
The Effect of The combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart disease	Three months of follow up	correlate the serum level of statin and SGLT2i when given as polytherapy with ECG in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)

Countries

Egypt

Contacts

Primary ContactRaghda Roshdy

Raghda.hussien@pharm.bsu.edu.eg01010647666

Backup ContactMarwa Kamal

mka05@fayoum.edu.eg01067789982

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026